Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018
August 8, 2018 4:05 PM EDTReports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018
RANCHO CUCAMONGA, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended June 30, 2018.
Second Quarter Highlights
Net revenues of $71.0 million for the second quarterGAAP net loss of $2.8 million, or $0.06 per diluted share, for the second quarterAdjusted non-GAAP net income of $1.2 million, or $0.03 per diluted share, for the second quarterDr. Jack Zhang, Amphastars CEO, commented: We had an exciting three months with FDA... More
